Other Information.
+Added: None of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted , modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2024, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:
+Added: On March 26, 2024 , Sean A.
+Added: McCarthy , our Chief Executive Officer , terminated a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) and originally adopted on June 01, 2023 , for the sale of up to 109,768 shares of the Company’s common stock until February 07, 2025 .
CytomX Therapeutics, Inc.
3 unchanged sentences
Certificate of Amendment to Amended and Restated Certificate of Incorporation of CytomX Therapeutics, Inc.
−Removed: Amended and Restated Bylaws.
+Added: Amended and Restated Bylaws of CytomX Therapeutics, Inc., effective March 20, 2024.
Reference is made to Exhibits 3.1 through 3.2.
Specimen Common Stock Certificate
−Removed: Form of Pre-Funded Warrant
−Removed: Form of Tranche Warrant
−Removed: Transition Agreement effective as of August 22, 2023 by and between CytomX Therapeutics, Inc., and AbbVie Global Enterprises Ltd.
+Added: Amendment No.
+Added: 4 to the Collaboration and License Agreement, dated as of March 28, 2024, by and between CytomX Therapeutics, Inc.
+Added: and Amgen, Inc.
Certification of Chief Executive Principal required by Rule 13a-14(a) or Rule 15d-14(a).
15 unchanged sentences
CytomX Therapeutics, Inc.
−Removed: November 7, 2023
Chief Executive Officer and Chairman
(Principal Executive Officer)
−Removed: November 7, 2023
/s/ Christopher W.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.